search
Back to results

ALLPS VERSUS PVO Randomized Controlled Trial (ALPPS)

Primary Purpose

Liver Tumors Not Resectable in One Surgical Procedure

Status
Terminated
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Associating liver partition and portal vein ligation for staged hepatectomy
Portal vein embolization or ligation
Sponsored by
University of Zurich
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Liver Tumors Not Resectable in One Surgical Procedure

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria: •Patient may have primary or secondary hepatic malignancies with a FLR/TLV < 30% or a FLR/BW ratio of < 0.5 for patients with normal liver function (defined as normal transaminases, normal bilirubin, normal factor V, and normal PT/INR). In case of injury due to chemotherapy, known high grade steatosis, or cholestasis > 50 mmol/L, patient may be enrolled into the trial if FLR/TLV is < 40% or FLR/BW ratio < 0.8.

  • Patient must have extensive liver tumors that would require portal vein embolization or a two-stage hepatectomy and portal vein embolization or ligation by the judgment of surgeons in the tumor board.
  • Patient may have extrahepatic disease as long as it may be addressed after liver surgery and there is a tumor board decision to proceed with liver resection (mostly applicable to CRC metastases).
  • Patient may have received previous chemotherapy.
  • In cases of cholestasis, preoperative drainage procedures (PTC or ERCP) are left up to judgement of physicians.
  • Patient must be = 18 years of age. The patient population over 65 years old needs to be carefully included based on comorbidities.
  • Patient may have undergone previous liver resection.
  • Patient's location must be such that proper staging and follow-up may be performed.
  • Patient's case must be presented at the Multidisciplinary Meeting attended by hepatobiliary surgeons, oncologists, hepatologists, and radiologists, or must be approved directly by Dr. Strasberg or Dr. Chapman.

Exclusion criteria: •Patient must not have any significant concomitant diseases rendering him/her unsuitable for major liver surgery by the judgment of the physicians involved, especially if the patient is > 65 years old.

  • Patient must not have enrolled into a clinical trial within 4 weeks of study entry.
  • Patient must not have peritoneal carcinomatosis or other extensive extrahepatic disease.
  • Patient must not have advanced stages of carcinoma of the gallbladder (T3/T4)
  • Patient must not have issues such as drug and/or alcohol abuse.
  • Patient must not need major extrahepatic surgery (e.g. pancreas resection, gastric resection, rectal surgery) within 3 months of study entry.
  • Patient must not be a candidate for liver transplantation in case of HCC.
  • Patient must not be pregnant or breastfeeding. If a female of childbearing potential, patient must have a negative pregnancy test within 14 days of enrollment.

Sites / Locations

  • Washington University
  • Italian Hospital, Department of Surgery, Division of HPB surgery and Liver Transplatn Unit
  • University Hospital Zurich, Division of Visceral and Transplant Surgery

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

ALPPS

PVO

Arm Description

Patients undergo Liver partition and portal vein ligation to induce hypertrophy of the future liver remnant

Patient undergo portal vein embolization or ligation

Outcomes

Primary Outcome Measures

Liver free of tumors [ Time Frame: At 3 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures

rate of hypertrophy over time
Complications of treatment
Progression of disease
Progression free survival
Postoperative liver and renal function

Full Information

First Posted
January 22, 2013
Last Updated
June 8, 2015
Sponsor
University of Zurich
search

1. Study Identification

Unique Protocol Identification Number
NCT01775267
Brief Title
ALLPS VERSUS PVO Randomized Controlled Trial
Acronym
ALPPS
Official Title
ASSOCIATING LIVER PARTITION WITH PORTAL VEIN LIGATION FOR STAGED HEPATECTOMY (ALPPS) Versus Conventional Portal Vein Occlusion (PVO) for Resection of Liver Tumors Unresectable in One Step - a Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
June 2015
Overall Recruitment Status
Terminated
Why Stopped
Study stopped due to safety concerns in both study arms
Study Start Date
November 2012 (undefined)
Primary Completion Date
November 2015 (Anticipated)
Study Completion Date
November 2015 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Zurich

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This randomized phase II trial compares how well associating liver partition with portal vein ligation for staged hepatectomy (ALPPS) or portal vein occlusion (PVO) works in treating patients with liver cancer. Both treatments are types of 2-stage hepatectomies for removing liver cancer. ALPPS may be more effective than PVO in patients whose disease would traditionally be considered inoperable. Trial with surgical intervention

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Liver Tumors Not Resectable in One Surgical Procedure

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
7 (Actual)

8. Arms, Groups, and Interventions

Arm Title
ALPPS
Arm Type
Experimental
Arm Description
Patients undergo Liver partition and portal vein ligation to induce hypertrophy of the future liver remnant
Arm Title
PVO
Arm Type
Active Comparator
Arm Description
Patient undergo portal vein embolization or ligation
Intervention Type
Procedure
Intervention Name(s)
Associating liver partition and portal vein ligation for staged hepatectomy
Intervention Type
Procedure
Intervention Name(s)
Portal vein embolization or ligation
Primary Outcome Measure Information:
Title
Liver free of tumors [ Time Frame: At 3 months ] [ Designated as safety issue: No ]
Time Frame
2012 to 2015
Secondary Outcome Measure Information:
Title
rate of hypertrophy over time
Time Frame
2012 to 2015
Title
Complications of treatment
Time Frame
2012-2015
Title
Progression of disease
Description
Progression free survival
Time Frame
2012-2015
Title
Postoperative liver and renal function
Time Frame
2012 to 2015

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: •Patient may have primary or secondary hepatic malignancies with a FLR/TLV < 30% or a FLR/BW ratio of < 0.5 for patients with normal liver function (defined as normal transaminases, normal bilirubin, normal factor V, and normal PT/INR). In case of injury due to chemotherapy, known high grade steatosis, or cholestasis > 50 mmol/L, patient may be enrolled into the trial if FLR/TLV is < 40% or FLR/BW ratio < 0.8. Patient must have extensive liver tumors that would require portal vein embolization or a two-stage hepatectomy and portal vein embolization or ligation by the judgment of surgeons in the tumor board. Patient may have extrahepatic disease as long as it may be addressed after liver surgery and there is a tumor board decision to proceed with liver resection (mostly applicable to CRC metastases). Patient may have received previous chemotherapy. In cases of cholestasis, preoperative drainage procedures (PTC or ERCP) are left up to judgement of physicians. Patient must be = 18 years of age. The patient population over 65 years old needs to be carefully included based on comorbidities. Patient may have undergone previous liver resection. Patient's location must be such that proper staging and follow-up may be performed. Patient's case must be presented at the Multidisciplinary Meeting attended by hepatobiliary surgeons, oncologists, hepatologists, and radiologists, or must be approved directly by Dr. Strasberg or Dr. Chapman. Exclusion criteria: •Patient must not have any significant concomitant diseases rendering him/her unsuitable for major liver surgery by the judgment of the physicians involved, especially if the patient is > 65 years old. Patient must not have enrolled into a clinical trial within 4 weeks of study entry. Patient must not have peritoneal carcinomatosis or other extensive extrahepatic disease. Patient must not have advanced stages of carcinoma of the gallbladder (T3/T4) Patient must not have issues such as drug and/or alcohol abuse. Patient must not need major extrahepatic surgery (e.g. pancreas resection, gastric resection, rectal surgery) within 3 months of study entry. Patient must not be a candidate for liver transplantation in case of HCC. Patient must not be pregnant or breastfeeding. If a female of childbearing potential, patient must have a negative pregnancy test within 14 days of enrollment.
Facility Information:
Facility Name
Washington University
City
St. Louis
State/Province
Missouri
Country
United States
Facility Name
Italian Hospital, Department of Surgery, Division of HPB surgery and Liver Transplatn Unit
City
Buenos Aires
Country
Argentina
Facility Name
University Hospital Zurich, Division of Visceral and Transplant Surgery
City
Zurich
State/Province
ZH
ZIP/Postal Code
8091
Country
Switzerland

12. IPD Sharing Statement

Learn more about this trial

ALLPS VERSUS PVO Randomized Controlled Trial

We'll reach out to this number within 24 hrs